H2020-JTI-IMI2-2015-08-single-stage

Suggested coordinators

Organisations that coordinated the most funded projects under this call.

• ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1 coordinated
• FOHM1 coordinated
• LSHTM1 coordinated
• SVA1 coordinated

Strong partners

Frequent participants in this call’s funded projects (research, universities, public bodies, and mixed types).

• INSERM3 projects · FR
• INMI2 projects · IT
• ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1 projects · FR
• FOHM1 projects · SE
• LSHTM1 projects · UK
• SVA1 projects · IT
• Leiden University Medical Center1 projects · NL
• BNI1 projects · DE
• BIOTECH INVESTISSEMENT1 projects · FR
• CERMEL1 projects · GA

Industry partners

Companies and SMEs that appear often in this call’s historical projects.

• BIOTECH INVESTISSEMENT1 projects · sme
• CEPHEID EUROPE1 projects · company
• CORIS BIOCONCEPT SPRL1 projects · sme
• EXCELLGENE SA1 projects · sme
• INSERM TRANSFERT SA1 projects · company
• Janssen Vaccines (f.k.a. Crucell Holland B.V.)1 projects · company
• MERCK SHARP & DOHME CORP1 projects · company
• MICROBIOTEC SRL1 projects · sme
• OLIGOVAX1 projects · sme
• RD-BIOTECH1 projects · sme
• VAXEAL RESEARCH1 projects · sme

Typical consortium size

Derived from historical funded projects linked to this call.

Partners per project

median 13 · avg 13.25

range 10 – 17 organisations

Country spread (sample)

18 countries

11–15 partner organisations (from median 13.0 in this call’s projects) · 18 countries appear often in the participant sample

Similar past projects

Largest EU contributions in this call — useful references for consortium patterns.

• EBOVAC3€29,402,656
• VSV-EBOPLUS€8,553,750
• PEVIA€6,189,570
• VHFMoDRAD€3,316,013